Literature DB >> 24146380

Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.

Egbert Oosterwijk1.   

Abstract

Four different carbonic anhydrases are expressed in the human nephron, the functional unit of the kidney. These are specifically expressed in different nephron segments, emphasizing the critical role carbonic anhydrases play in maintaining the homeostasis of this crucial organ.Whereas the localization of carbonic anhydrases in the kidney has been long established, interest in carbonic anhydrases has increased dramatically for renal cancer, in particular for the clear cell variant of renal cell carcinoma (ccRCC) because carbonic anhydrase IX is specifically expressed in ccRCC. Therefore carbonic anhydrase IX is being studied as potential diagnostic and therapeutic target, despite carbonic anhydrase IX expression in non-renal tissues.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24146380     DOI: 10.1007/978-94-007-7359-2_10

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  9 in total

1.  Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.

Authors:  Derek P Logsdon; Michelle Grimard; Meihua Luo; Safi Shahda; Yanlin Jiang; Yan Tong; Zhangsheng Yu; Nicholas Zyromski; Ernestina Schipani; Fabrizio Carta; Claudiu T Supuran; Murray Korc; Mircea Ivan; Mark R Kelley; Melissa L Fishel
Journal:  Mol Cancer Ther       Date:  2016-08-17       Impact factor: 6.261

2.  Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.

Authors:  Jeannette C Oosterwijk-Wakka; Mirjam C A de Weijert; Gerben M Franssen; William P J Leenders; Jeroen A W M van der Laak; Otto C Boerman; Peter F A Mulders; Egbert Oosterwijk
Journal:  Neoplasia       Date:  2015-02       Impact factor: 5.715

3.  Transcriptome Sequencing (RNAseq) Enables Utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development.

Authors:  Oystein Eikrem; Christian Beisland; Karin Hjelle; Arnar Flatberg; Andreas Scherer; Lea Landolt; Trude Skogstrand; Sabine Leh; Vidar Beisvag; Hans-Peter Marti
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

4.  Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.

Authors:  Fenil Shah; Derek Logsdon; Richard A Messmann; Jill C Fehrenbacher; Melissa L Fishel; Mark R Kelley
Journal:  NPJ Precis Oncol       Date:  2017-06-08

5.  Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival.

Authors:  Derek P Logsdon; Fenil Shah; Fabrizio Carta; Claudiu T Supuran; Malgorzata Kamocka; Max H Jacobsen; George E Sandusky; Mark R Kelley; Melissa L Fishel
Journal:  Sci Rep       Date:  2018-09-13       Impact factor: 4.379

6.  PET imaging and pharmacological therapy targeting carbonic anhydrase-IX high-expressing tumors using US2 platform based on bivalent ureidosulfonamide.

Authors:  Shimpei Iikuni; Hiroyuki Watanabe; Yoichi Shimizu; Yuji Nakamoto; Masahiro Ono
Journal:  PLoS One       Date:  2020-12-09       Impact factor: 3.240

7.  Contribution of the Mitochondrial Carbonic Anhydrase (MoCA1) to Conidiogenesis and Pathogenesis in Magnaporthe oryzae.

Authors:  Yuejia Dang; Yi Wei; Wajjiha Batool; Xicen Sun; Xiaoqian Li; Shi-Hong Zhang
Journal:  Front Microbiol       Date:  2022-02-17       Impact factor: 5.640

Review 8.  Review of the Diagnostic Evaluation of Normal Anion Gap Metabolic Acidosis.

Authors:  Kenrick Berend
Journal:  Kidney Dis (Basel)       Date:  2017-09-01

9.  Cancer radiotheranostics targeting carbonic anhydrase-IX with 111In- and 90Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy.

Authors:  Shimpei Iikuni; Masahiro Ono; Hiroyuki Watanabe; Yoichi Shimizu; Kohei Sano; Hideo Saji
Journal:  Theranostics       Date:  2018-04-30       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.